admin – eisai china lnc.-pg电子app

eisai and biogen announced today that the ministry of food and drug safety
(mfds) in south korea has approved humanized anti-soluble aggregated amyloid-beta (aβ)
monoclonal antibody “leqembi®” (lecanemab) for treatment in adult patients with mild cognitive
impairment due to alzheimer’s disease (ad) or mild ad (early ad).

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that the injection formulation of its in-house discovered antiepileptic drug (aed) fycompa® (perampanel hydrate) for intravenous (iv) infusion has been launched in japan.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has submitted a marketing authorization application in japan for its in-house discovered fibroblast growth factor (fgf) receptor (fgfr1, fgfr2, fgfr3) selective tyrosine kinase inhibitor tasurgratinib succinate (generic name, development code: e7090, “tasurgratinib”) for biliary tract cancer with fgfr2 gene fusion. in japan, tasurgratinib has received orphan drug designation for a prospective indication for unresectable biliary tract cancer with fgfr2 gene fusion by the ministry of health, labour and welfare, (mhlw). under this system, this application will be subject to priority review.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and msd k.k. (headquarters: tokyo, president: kyle tattle, “msd”), a subsidiary of merck & co., inc., kenilworth, n.j., u.s.a., (known as msd outside the united states and canada) announced today that eisai has submitted an application in japan for the additional indication of its in-house discovered and developed multiple receptor tyrosine kinase inhibitor, lenvima® (generic name: lenvatinib mesylate), in combination with merck & co., inc., kenilworth, n.j., u.s.a.’s keytruda® (generic name: pembrolizumab) as a treatment for patients with advanced renal cell carcinoma (rcc). this is the first application to be submitted in japan for this combination therapy.